MapLight Therapeutics, Inc. (NASDAQ:MPLT) is likely one of the
8 Healthcare Stocks Insiders Are Buying. On April 8, 2026, Needham initiated protection of MapLight Therapeutics, Inc. (NASDAQ:MPLT) with a Purchase score and a $37 worth goal. Needham mentioned the muscarinic class might be “disruptive” throughout a number of indications, together with schizophrenia and Alzheimer’s illness psychosis, and famous ML-007C-MA could also be “differentiated” from Cobenfy on tolerability and comfort, with potential to succeed in $1.5B in gross sales by 2035.
On April 7, 2026, TD Cowen initiated protection of MapLight Therapeutics with a Purchase score, highlighting its pipeline concentrating on central nervous system and neuropsychiatric circumstances. TD Cowen mentioned the lead asset ML-007C-MA is positioned to enhance on Cobenfy’s profile in schizophrenia, with a Section II readout anticipated in Q3, and views the shares as undervalued primarily based on this chance.
Final month, Canaccord initiated protection of MapLight Therapeutics with a Purchase score and a $35 worth goal. Canaccord mentioned the corporate’s concentrate on novel CNS therapeutics helps its schizophrenia alternative and recommends shopping for the inventory forward of Section 2 information for ML-007C-MA anticipated in Q3.
MapLight Therapeutics, Inc. (NASDAQ:MPLT) develops therapies for central nervous system issues.
Whereas we acknowledge the potential of MPLT as an funding, we consider sure AI shares provide larger upside potential and carry much less draw back threat. When you’re in search of a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
